Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Vellanki's presentation is scheduled for September 13 at 7:00 a.m. ET. Interested parties can access the presentation via a webcast link or through the Rain website. A replay will be available for 30 days post-event. Rain focuses on precision oncology, developing therapies like milademetan, a small molecule MDM2 inhibitor, targeting various cancers.

NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23^rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Additional details can be found below:

Date: Monday, September 13, 2021
Time: 7:00 a.m. ET
Location: Webcast Link – or on the Rain website (click here)

A replay of the presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com

FAQ

What is the date and time of Rain's presentation at the 23rd Annual Global Investment Conference?

Rain's presentation is scheduled for September 13, 2021, at 7:00 a.m. ET.

Where can I watch the Rain Therapeutics presentation?

The presentation can be viewed through a webcast link provided in the press release or on the Rain website.

What is milademetan and how is it related to Rain Therapeutics?

Milademetan is Rain's lead product candidate, a small molecule oral inhibitor of MDM2, targeting oncogenic drivers in various cancers.

How long will the replay of Rain's presentation be available?

The replay will be available on the Rain website for 30 days after the presentation.

What type of company is Rain Therapeutics?

Rain Therapeutics is a late-stage precision oncology company focusing on developing targeted therapies based on genetic selection.